oligonucleotidebas
drug
receiv
consider
attent
capac
modul
gene
express
specif
consequ
found
applic
treatment
mani
human
acquir
genet
diseas
clinic
translat
often
hamper
poor
biodistribut
howev
cellpenetr
peptid
cpp
appear
possibl
increas
cellular
deliveri
nonperm
biomolecul
nucleic
acid
review
focus
cppdeliveri
sever
class
oligonucleotid
on
name
antisens
oligonucleotid
splice
switch
oligonucleotid
sso
sirna
two
main
strategi
use
transport
on
cpp
coval
conjug
appropri
chargeneutr
analogu
noncoval
complex
use
sirna
deliveri
essenti
chemic
synthesi
mechan
cellular
intern
variou
applic
review
comprehens
coverag
enorm
amount
publish
data
possibl
instead
emphasi
put
strategi
proven
effect
anim
model
import
human
diseas
exampl
taken
author
expertis
recent
year
dramat
reevalu
gene
regul
gene
express
modal
two
major
set
discoveri
centr
key
role
noncod
rna
particular
involv
rna
interfer
rnai
pathway
well
mosaic
structur
eukaryot
gene
antisens
strategi
propos
two
decad
ago
artifici
regul
eukaryot
gene
express
cultur
cell
via
hybrid
short
on
mrna
target
pioneer
work
stephenson
zamecnik
immens
potenti
strategi
principl
requir
knowledg
target
mrna
sequenc
quickli
realiz
within
academ
industri
laboratori
interestingli
mother
natur
also
exploit
potenti
convincingli
demonstr
bacteria
later
eukaryot
abil
capit
potent
biochem
genet
tool
best
demonstr
antisens
concept
exploit
came
discoveri
antisens
gene
abl
control
transcript
bacteria
less
experiment
evid
eukaryot
cell
fine
tune
express
target
gene
howev
natur
antisens
rna
turn
long
highli
structur
attempt
use
knowledg
design
synthet
antisens
gene
prove
disappoint
studi
far
antisens
field
instead
focuss
short
singlestrand
dna
mimic
hybrid
allow
recruit
cellular
enzym
rnase
h
consequ
lead
destruct
rna
target
somewhat
unexpectedli
eukaryot
code
gene
transcrib
immatur
mrna
precursor
splice
complex
nuclear
machineri
lead
intron
remov
becam
rapidli
realiz
major
outcom
possibl
exon
reassort
case
major
human
gene
importantli
term
potenti
clinic
translat
sever
human
diseas
associ
dysfunct
splice
machineri
preferenti
use
one
splice
event
rather
anoth
intervent
process
exon
select
use
low
molecular
weight
drug
turn
difficult
promis
strategi
propos
instead
ryszard
kole
colleagu
detail
section
issu
contrast
classic
antisens
strategi
splice
switch
oligonucleotid
sso
design
prevent
promot
insert
exon
high
affin
bind
obligatori
splice
sequenc
nuclear
premrna
exampl
donor
acceptor
splice
site
therefor
rnase
hincompet
analogu
must
use
discoveri
rna
interfer
fire
et
al
also
revolution
concept
gene
express
regul
current
detail
knowledg
rnai
process
recognit
rnainduc
silenc
complex
risc
led
possibl
ration
design
synthesi
artifici
sirna
abl
recogn
mrna
sole
basi
sequenc
rnase
hcompet
antisens
sequencespecif
recognit
rna
target
lead
degrad
riscassoci
nucleas
sever
hundr
human
gene
identifi
code
short
stemloop
structur
known
micro
rna
mirna
process
allow
target
mrna
mani
mrna
target
identifi
astonishingli
mirna
need
hybrid
entir
sequenc
promot
downregul
mrna
target
consequ
singl
mirna
abl
regul
express
complex
set
mrna
often
relat
term
cellular
function
although
still
incomplet
ongo
studi
show
specif
set
mirna
control
cellular
function
dysregul
express
associ
mani
human
diseas
regul
level
certain
mirna
interfer
bind
mrna
target
heavili
explor
strategi
synthet
antisens
on
sso
sirna
mirna
becom
routin
invalu
tool
dissect
cellular
function
effici
transfect
laboratori
cell
line
use
commerci
avail
reagent
cation
lipid
formul
howev
system
vivo
administr
plagu
toxic
low
effici
presenc
serum
protein
therapeut
develop
centr
use
nake
on
thu
met
limit
success
inde
two
decad
therapeut
develop
led
three
fda
approv
drug
two
use
easiertomanag
topic
ocular
applic
fomivirsen
antisens
treatment
ocular
cytomegaloviru
infect
immunocompromis
patient
ranibizumab
aptam
treatment
macular
degener
promis
recent
approv
us
yet
europ
mipomersen
antisens
treatment
homozyg
famili
hypercholesterolemia
capit
accumul
phosphorothio
ps
on
liver
system
administr
encourag
small
scale
clinic
data
also
report
treatment
duchenn
muscular
dystrophi
phosphorothio
on
drisapersen
phosphorodiamid
morpholino
oligonucleotid
pmo
eteplirsen
extens
discuss
later
section
chapter
despit
success
gener
agre
degrad
biolog
fluid
passag
across
cellular
barrier
intracellular
traffick
limit
factor
nucleic
acidsbas
therapi
extens
search
chemic
modif
improv
metabol
stabil
significantli
well
affin
rna
target
extent
reduc
offtarget
effect
chemic
modif
significantli
improv
cellular
uptak
tissu
target
howev
design
effici
nontox
deliveri
vector
onbas
drug
therefor
becom
major
concern
academ
industri
laboratori
among
mani
propos
tool
deliveri
cell
penetr
peptid
cpp
appear
easi
implement
strategi
led
encourag
data
least
murin
model
human
diseas
review
later
chapter
review
pretend
exhaust
restrict
cpp
deliveri
nucleic
acidsbas
drug
mainli
sso
sirna
deliveri
strategi
turn
effici
anim
model
human
diseas
har
cation
peptid
deliv
drug
across
biolog
membran
first
attempt
ryser
colleagu
demonstr
anticanc
drug
could
deliv
polyllysin
pll
conjug
drug
resist
cell
vitro
vivo
mous
model
likewis
chemic
conjug
antisens
on
pll
led
gener
potent
antivir
activ
sever
vitro
model
viral
infect
unfortun
conjug
poorli
character
view
polydispers
charact
commerci
pll
prepar
importantli
led
acut
cytotox
upon
system
administr
mice
discov
serendipit
virologist
much
shorter
stretch
cation
peptid
could
promot
cellular
uptak
macromolecul
exampl
found
full
size
purifi
tat
protein
transactiv
ltr
promot
incub
cell
astonishingli
tat
protein
abl
conjug
promot
cellular
intern
nonperm
protein
pave
way
use
tat
deliveri
vector
biomolecul
along
line
purifi
antennapedia
protein
drosophila
abl
exert
transcript
activ
incub
nerv
cell
properti
ascrib
short
peptid
name
penetratin
dissect
tat
protein
also
show
cell
penetr
due
small
basic
amino
acidsrich
peptid
known
tat
peptid
initi
studi
cellular
traffick
penetratin
tat
suggest
unusu
nonreceptor
depend
mechan
direct
transloc
across
plasma
membran
although
challeng
later
detail
section
mechan
possibl
use
call
cellpenetr
peptid
cpp
nonvir
deliveri
vector
biomolecul
foster
larg
interest
mani
cpp
rapidli
discov
propos
vector
transport
variou
drug
across
biolog
membran
start
low
molecular
mass
drug
larg
molecular
entiti
nanoparticl
cpp
design
transport
chemic
conjug
cargo
see
tabl
sinc
chemic
conjug
purif
neg
charg
on
popular
cation
cpp
turn
difficult
applic
concern
chargeneutr
analogu
peptid
nucleic
acid
pna
pmo
see
section
advanc
studi
involv
use
conjug
rna
splice
regul
earli
work
describ
use
penetratin
deliveri
conjug
ps
on
transportan
anoth
popular
cpp
pna
transport
unexpectedli
wellcharacter
hela
cell
assay
posit
readout
fig
splice
redirect
use
pna
pmo
oligom
conjug
variou
standard
cpp
tat
penetratin
oligoarginin
achiev
research
group
hela
pluc
cell
stabli
transfect
construct
code
sequenc
luciferas
gene
interrupt
mutat
intron
human
gene
mutat
creat
site
activ
site
mask
site
rnase
hincompet
antisens
restor
product
function
luciferas
mrna
protein
assay
provid
kole
colleagu
allow
reliabl
easi
implement
compar
evalu
analogu
ondeliveri
vector
intron
point
mutat
globin
gene
activ
cryptic
splice
site
lead
aberr
splice
intron
consequ
nonfunct
protein
mask
mutat
site
stericblock
reorient
splice
machineri
toward
complet
remov
intron
lead
product
correctli
splice
mrna
mutat
intron
introduc
code
region
report
luciferas
gene
construct
stabli
transfect
hela
cell
avail
atcc
luciferas
express
easili
monitor
enzymat
pcr
assay
advantag
provid
posit
readout
low
background
larg
dynam
rang
adopt
mani
laboratori
field
thu
allow
easi
comparison
extens
studi
cellular
traffick
reveal
cppon
conjug
effici
taken
cell
remain
stuck
endocyt
vesicl
keep
hypothesi
incub
chloroquin
endosomolyt
drug
saponin
membranepermeabil
agent
allow
bypass
restrict
similar
conclus
reach
use
wellcharacter
assay
nielsen
group
understand
mechan
cell
uptak
use
cpp
via
comparison
literatur
data
prove
extrem
difficult
sinc
behaviour
cpp
seem
strongli
influenc
experiment
condit
among
relev
factor
cpp
sequenc
type
cargo
concentr
seem
crucial
foster
endocytosi
direct
transloc
cell
type
first
data
show
strong
activ
hela
splice
redirect
assay
obtain
deriv
oligoarginin
spatial
distribut
guanidinium
side
chain
optim
use
nonnatur
aminohexano
acid
spacer
similarli
addit
arginin
residu
nterminu
penetratin
also
result
strong
activ
hela
assay
pna
conjug
led
develop
sever
argininerich
peptid
pmo
conjug
use
muscl
cell
vivo
mous
model
dmd
outlin
section
addit
coval
conjug
cpp
design
use
complex
particularli
sirna
deliveri
tabl
previous
allud
chemic
conjug
purif
on
sirna
cation
cpp
difficult
achiev
exampl
case
on
heitz
divita
group
describ
new
class
cpp
mpg
lead
compound
complex
neg
charg
on
essenti
electrostat
interact
complex
peptid
detail
section
sinc
practic
cpp
high
cation
charg
due
ly
arg
residu
prove
extrem
hard
technic
coval
conjug
cpp
standard
neg
charg
phosphodiest
phosphorothio
on
aggreg
precipit
occur
possibl
thiol
linkerfunctionalis
on
exampl
mixmer
steric
block
on
conjug
cysteinefunctionalis
classic
cpp
tat
penetratin
give
disulphid
linkag
conjug
carri
presenc
denatur
agent
formamid
way
found
fluoresc
version
conjug
taken
much
better
endosom
compart
model
hela
cell
unconjug
version
releas
nucleu
gener
steric
block
rna
target
activ
prove
achiev
disulphid
linkag
also
thought
compat
suffici
conjug
stabil
use
system
deliveri
although
lung
deliveri
disulphidelink
penetratin
tat
conjug
sirna
attempt
thu
rare
exampl
peptideconjug
neg
charg
on
use
vivo
gener
utilis
thiolmaleimid
linkag
peptid
fig
one
case
synthesi
aminohexyl
linker
result
amino
group
react
bifunct
n
gammamaleimidobutyrloxi
succinimid
gmb
reagent
give
maleimid
deriv
maleimid
group
subsequ
react
cyscontain
peptid
cation
cpp
known
furnish
desir
conjug
fig
surprisingli
chain
aggreg
report
conjug
reaction
altern
conveni
noncation
peptid
discov
phage
display
techniqu
functionalis
nterminu
reaction
maleimidopropion
acid
final
stage
peptid
synthesi
purif
conjug
phosphorothio
synthes
linker
fig
conjug
design
enhanc
uptak
muscl
heart
due
use
home
peptid
select
phage
display
method
noncation
home
peptid
like
explor
deliveri
on
specif
tissu
type
inde
recent
report
phageselect
space
peptid
conjug
coval
sirna
show
enhanc
skin
penetr
one
might
also
expect
increas
use
conjug
use
modern
click
chemistri
via
coppercatalys
reaction
azido
function
alkyn
group
peptid
contain
clickabl
function
contain
function
despit
larg
bodi
literatur
use
peptideconjug
pna
cell
cultur
surprisingli
exampl
use
vivo
case
short
peptid
attach
pna
assembl
directli
n
cterminu
pna
chain
solidphas
synthesi
without
need
specif
conjug
step
amid
coupl
protect
amino
acid
ident
protect
pna
monom
long
compat
protect
group
scheme
use
standard
synthes
pna
common
add
ly
residu
case
particularli
enhanc
aqueou
solubl
pna
thu
first
report
pna
activ
involv
mere
use
ly
ntermin
functionalis
pna
ly
residu
effect
act
cpp
vivo
splice
assay
use
green
fluoresc
protein
report
upregul
redirect
splice
pna
vivo
result
obtain
use
ly
deriv
pna
synthes
continu
way
nterminu
pna
result
show
ly
pna
conjug
rapidli
clear
circul
distribut
rel
broadli
mous
highest
concentr
reach
liver
kidney
spleen
low
amount
detect
lung
heart
skelet
muscl
test
howev
vivo
analysi
extend
amphipath
ly
leucontain
dpeptid
anoth
rich
arg
homoarg
pna
conjug
synthes
continu
solid
phase
neither
show
splice
redirect
liver
lysleu
peptidepna
conjug
show
activ
kidney
show
signific
activ
adipos
tissu
howev
lack
potenc
compar
rnaseh
activ
on
perceiv
toxic
profil
high
dose
led
abandon
peptidepna
conjug
drug
modal
isi
pharmaceut
continu
synthes
nuclear
local
signal
nl
peptid
pkkkrkv
attach
pna
also
report
activ
sever
combin
immunodefici
scid
mous
model
intron
target
cmyc
burkitt
lymphomaaim
therapi
penetratin
peptid
synthes
continu
cterminu
triplexform
pna
target
chromosom
dna
genet
modif
haematopoiet
progenitor
cell
mice
promis
microrna
knockdown
result
obtain
also
antisens
lyspna
ly
deriv
test
mous
spleen
target
recent
antimicrorna
pna
disulphideconjug
fig
tumourtarget
phlip
peptid
shown
potent
activ
mous
model
lymphoma
exampl
peptidepna
activ
vivo
synthes
continu
solidphas
assembl
argrich
cpp
relat
conjug
thioether
bridg
reaction
ctermin
cy
residu
peptid
ntermin
bromoacetyl
group
pna
fig
conjug
activ
intramuscular
inject
mdx
mous
model
duchenn
muscular
dystrophi
dmd
later
higher
activ
found
vivo
use
pmo
rather
pna
materi
despit
result
mix
fortun
vivo
cpp
conjug
pna
materi
deserv
investig
especi
case
tissu
harder
reach
type
new
method
parallel
synthesi
array
cpppna
conjug
known
selpepcon
could
prove
use
prescreen
suitabl
drug
candid
cell
assay
exampl
intramuscular
deliveri
far
major
success
vivo
use
cpp
conjug
utilis
pmo
cargo
applic
cpppmo
muscular
dystrophi
outlin
section
regard
peptidepmo
ppmo
synthesi
suffic
say
possibl
date
use
continu
synthesi
method
ppmo
conjug
sinc
synthesi
restrict
commerci
pmo
supplier
method
conjug
therefor
limit
avail
commerci
regard
functionalis
pmo
instead
must
employ
unfunctionalis
pmo
practic
cpp
use
pmo
date
argrich
start
initi
observ
moulton
colleagu
earli
work
involv
use
bifunct
crosslink
coupl
pmo
maleimid
linkag
peptid
fig
later
directli
conjug
amid
linkag
use
ctermin
activ
peptid
fig
also
carri
commerci
avail
aminolink
functionalis
pmo
direct
coupl
ctermin
carboxyl
acid
peptid
amid
link
gener
secondari
amin
group
coupl
directli
ctermin
carboxyl
acid
pmo
via
amid
link
fig
direct
amid
conjug
necessari
argcontain
peptid
chemic
protect
howev
lyscontain
cpp
requir
protect
group
epsilon
amino
group
remov
conjug
direct
conjug
unfunctionalis
pmo
also
allow
peptid
conjug
pmo
contain
exampl
alkyn
function
allow
azid
click
coupl
fluoresc
label
ppmo
addit
click
chemistri
conjug
featur
adapt
ppmo
selpepcon
method
parallel
conjug
synthesi
fig
combin
compat
conjug
techniqu
use
click
chemistri
like
domin
futur
ppmo
synthesi
method
term
muscular
dystrophi
describ
larg
group
hereditari
diseas
character
progress
weak
degener
skelet
muscl
varieti
gene
therapi
develop
clinic
genet
heterogen
group
disord
includ
antisens
mediat
splice
modul
sso
recent
advanc
place
duchenn
muscular
dystrophi
dmd
forefront
develop
sso
therapi
order
overcom
remain
obstacl
success
approach
peptideconjug
sso
extens
investig
anim
model
dmd
dmd
common
subtyp
muscular
dystrophi
uk
onlin
mendelian
inherit
man
omim
databas
refer
affect
one
new
born
boy
sever
xlink
recess
diseas
result
mutat
dmd
gene
disord
character
progress
muscl
degener
wast
along
emerg
respiratori
cardiac
complic
ultim
lead
prematur
death
major
mutat
underli
dmd
genom
delet
encompass
multipl
exon
therebi
produc
prematur
truncat
open
read
frame
result
absenc
dystrophin
protein
dystrophin
integr
compon
dystrophin
associ
protein
complex
dapc
form
crucial
connect
intracellular
actincytoskeleton
extracellular
matrix
exon
skip
therapi
utilis
sso
target
specif
region
dmd
transcript
induc
exclus
individu
exon
lead
restor
aberr
read
frame
result
product
intern
delet
yet
larg
function
dystrophin
protein
follow
develop
anim
model
two
ao
chemistri
undergon
proofofconcept
studi
repeat
system
doseescal
studi
complet
clinic
trial
set
system
administr
pmo
omep
sso
yield
specif
exon
exclus
partial
restor
dystrophin
protein
peripher
muscl
dmd
boy
despit
undoubt
potenti
exon
skip
therapi
dmd
success
applic
approach
current
limit
rel
ineffici
target
skelet
muscl
well
inadequ
target
sso
affect
tissu
heart
cation
cpp
may
coadminist
conjug
sso
shown
dramat
improv
deliveri
induc
high
level
dystrophin
correct
muscl
compar
low
dose
major
work
perform
mdx
dmd
mous
model
wide
utilis
model
dmd
field
dystroph
murin
phenotyp
aris
result
spontan
mutat
exon
encod
prematur
termin
site
thu
prevent
product
dystrophin
protein
target
exclus
exon
mous
model
therapeut
strategi
patient
restor
product
dystrophin
protein
major
cpp
utilis
dmd
field
tabl
may
coval
link
pmo
howev
anoth
class
noncoval
peptid
transportan
famili
engin
deliv
anion
sso
detail
section
number
modif
stearyl
gave
rise
cpp
capabl
induc
high
splice
correct
vitro
murin
mdx
myotub
tabl
note
vivo
efficaci
cpp
yet
assess
coval
class
cpp
compris
subtyp
specif
oligoarginin
deriv
phage
peptid
penetratin
deriv
oligoarginin
space
acid
andor
exhibit
high
splice
effici
serum
stabil
vitro
rxr
peptid
first
cpp
conjug
administ
mdx
mous
rang
dose
timeinterv
via
differ
deliveri
rout
gener
singl
intraven
administr
induc
high
dystrophin
exon
skip
skelet
muscl
diaphragm
first
time
heart
anoth
argininerich
peptid
rxrrbr
peptid
bpeptid
identifi
screen
use
splice
report
mous
model
also
gave
rise
impress
exon
skip
notabl
heart
deliv
use
higher
dose
via
retroorbit
rout
improv
cardiac
function
resist
dobutamin
stress
test
improv
end
systol
volum
end
diastol
volum
also
observ
identif
phage
motif
phage
displaylibrari
allow
specif
home
target
tissu
peptid
preferenti
bind
muscl
cardiac
tissu
identifi
specif
treatment
dmd
includ
muscl
specif
peptid
msp
exhibit
enhanc
vivo
muscl
bind
capac
peptid
reveal
better
splice
effici
msp
peptid
exhibit
moder
improv
splice
activ
nake
sso
benefici
tissu
target
attribut
phage
peptid
may
enhanc
combin
deliveri
effici
cpp
develop
chimer
peptid
demonstr
msp
coupl
bpeptid
determin
combin
efficaci
mdx
mice
specif
orient
peptid
crucial
dystrophin
splice
activ
coupl
configur
bmsppmo
reveal
fold
improv
skelet
muscl
restor
compar
bpmo
howev
improv
dystrophin
restor
observ
cardiac
muscl
recent
pnapmo
intern
peptid
pip
seri
deriv
parent
penetratin
peptid
subsequ
modif
includ
addit
arginin
residu
nterminu
addit
ctermin
cystein
residu
utilis
disulphid
conjug
method
fashion
group
peptid
establish
pip
sequenc
conform
consist
central
hydrophob
core
flank
either
side
argininerich
sequenc
addit
vivo
screen
pippmo
compound
carri
identifi
optim
cpp
dystrophin
splice
correct
mdx
mice
core
sequenc
ilfqi
retain
alter
composit
length
flank
region
number
arginin
residu
rang
number
placement
acid
x
b
spacer
residu
also
vari
flank
region
tabl
result
greatest
number
dystrophin
posit
fibr
follow
intramuscular
administr
tibiali
anterior
muscl
highli
effici
cpp
induc
highest
level
exon
skip
dystrophin
restor
bodi
wide
includ
heart
follow
singl
mgkg
intraven
administr
directli
compar
bpmo
shown
restor
consider
greater
dystrophin
protein
level
heart
intraven
administr
comparison
bpmo
compris
similar
arginin
sequenc
content
deduc
core
region
ilfqi
respons
splice
activ
heart
therefor
design
ident
flank
region
core
sequenc
alter
tabl
maintain
amino
acid
core
exhibit
greatest
dystrophin
splice
activ
heart
previou
lead
candid
fig
peptid
shorten
core
result
substanti
reduct
efficaci
cardiac
respiratori
complic
lead
caus
death
amongst
dmd
patient
abil
restor
cardiac
function
vital
compound
demonstr
restor
abil
long
term
low
dose
administr
studi
mgkg
month
timecours
dystrophin
protein
restor
heart
onset
cardiomyopathi
prevent
exercis
mdx
mous
model
unpublish
data
liver
kidney
toxic
assess
week
administr
pippmo
conjug
mdx
mice
sign
toxic
toxicolog
studi
current
pursu
howev
publish
yet
cours
continu
optimis
dose
pharmacokinet
toxic
underway
facilit
progress
class
cpp
clinic
trial
develop
cppon
conjug
treatment
dmd
serv
foundat
treatment
diseas
face
similar
antisens
deliveri
challeng
antisens
on
use
modul
rna
process
triplet
repeat
disord
myoton
dystrophi
omim
degen
diseas
aris
fig
immunohistochem
stain
dystrophin
follow
treatment
dystrophin
stain
tibiali
anterior
heart
untreat
mdx
treat
mdx
mice
treat
cohort
receiv
singl
intraven
mgkg
dose
tissu
harvest
week
later
expans
pathogen
microsatellit
repeat
within
noncod
region
either
dystrophia
myotonicaprotein
kinas
dmpk
cchctype
zinc
finger
nucleic
acid
bind
protein
cnbp
gene
loci
varieti
antisens
strategi
use
combat
effect
toxic
rna
expans
although
current
promis
use
steric
block
on
use
approach
on
design
bind
dmpk
repeat
region
therefor
prevent
detriment
sequest
rnabind
protein
within
expans
due
multisystem
natur
myoton
dystrophi
cpp
conjug
antisens
strategi
recent
test
mous
model
induc
bodi
wide
distribut
spinal
muscular
atrophi
omim
neuromuscular
disord
result
loss
motor
neuron
skelet
muscl
atrophi
autosom
recess
diseas
caus
mutat
surviv
motor
neuron
gene
relat
gene
undergo
altern
splice
due
singl
nucleotid
polymorph
therefor
lack
exon
major
transcript
result
low
protein
express
order
function
compens
loss
protein
patient
sso
use
promot
inclus
exon
transcript
therefor
increas
product
protein
substanti
headway
made
nake
sso
anim
model
sma
clinic
trial
ongo
howev
effect
deliveri
antisens
on
motor
neuron
cn
constitut
major
challeng
may
combat
cpp
conjug
describ
multipl
diseas
may
benefit
antisens
therapi
inde
reach
clinic
trial
demonstr
signific
therapeut
potenti
success
may
amass
util
cpp
rapidli
evolv
field
research
whilst
studi
pertain
toxic
biodistribut
underway
anticip
cppon
therapi
reach
clinic
trial
near
futur
amongst
antivir
applic
cpppna
design
sever
year
ago
target
transactiv
respons
element
tar
reassuringli
tatpna
found
nontox
mice
high
mgkg
dose
howev
vivo
antivir
studi
cpppna
publish
sinc
contrast
cpppmo
antivir
applic
plenti
rang
virus
dengu
cocksacki
ebola
marburg
virus
vivo
studi
cppdirect
antivir
deliveri
publish
involv
argrich
cpp
notabl
rxr
xb
r
f
conjug
pmo
tabl
exampl
rxr
xbpmo
block
viral
replic
human
respiratori
syncyti
viru
rsv
express
balbc
mice
pmo
sequenc
target
start
code
region
also
reduct
lung
viral
titr
seen
mice
treat
h
infect
h
infect
suggest
pmo
must
present
cell
soon
infect
impact
viru
product
promis
result
obtain
preand
postinfect
rxr
xbpmo
treatment
old
piglet
infect
porcin
reproduct
respiratori
syndrom
viru
prrsv
reduc
viremia
interstiti
pneumonia
rxr
xbpmo
conjug
pmo
target
genom
rna
strand
found
substanti
activ
nake
pmo
reduc
viral
titer
liver
mice
infect
murin
hepat
viru
mhv
coronaviru
protect
mice
tissueassoci
liver
damag
cpppmo
treatment
also
prolong
surviv
two
lethal
challeng
model
howev
case
high
dose
viral
challeng
delay
treatment
cpppmo
protect
evid
toxic
diseas
mice
ag
mice
treat
intraperiton
inject
rxr
xbpmo
target
sequenc
cs
region
dengu
viru
preinfect
postinfect
abl
increas
averag
surviv
time
day
viral
rebound
seen
eventu
similarli
dose
rxr
xbpmo
target
either
region
west
nile
viru
wnv
rna
partial
protect
mice
viral
challeng
higher
dose
caus
toxic
unconjug
pmo
efficaci
although
cpppmo
approach
promis
principl
target
viral
rna
altern
antivir
approach
involv
use
pmo
analogu
cation
piperazin
group
within
pmo
second
gener
pmo
known
gener
supplant
cpppmo
antivir
applic
review
cpppna
suggest
year
ago
target
specif
essenti
bacteri
gene
subsequ
cpppna
cpppmo
studi
extens
bacteri
cell
cultur
surprisingli
experi
show
vivo
efficaci
publish
first
proof
principl
vivo
shown
singl
intraven
inject
kff
kpna
target
acpp
essenti
gene
rna
administ
escherichia
coli
balbc
mice
min
bacteri
challeng
reduc
bacteri
blood
titr
enhanc
surviv
infect
mice
similar
result
obtain
argrich
rff
rxbpmo
conjug
target
acpp
gene
dose
mice
h
infect
e
coli
effect
potenc
vari
peptid
sequenc
investig
model
rxr
xb
found
potent
variou
argrich
cpp
studi
mice
recent
cpppna
target
rpod
gene
encod
rna
polymeras
primari
subunit
essenti
bacteri
growth
show
broad
inhibit
multidrugresist
escherichia
coli
salmonella
enterica
klebsiella
pneumonia
shigella
flexneri
cell
vivo
rxr
xb
cpp
pna
conjug
higher
activ
gener
kff
k
cpp
rff
rpmo
target
acpp
gyra
gene
found
highli
effect
increas
mous
surviv
time
mice
challeng
deadli
ame
strain
bacillu
anthraci
caus
agent
anthrax
suggest
treatment
anthraxinfect
human
might
one
day
becom
possibl
howev
like
case
pathogen
virus
cation
backbonecontain
pmo
although
achiev
effici
cpppmo
may
prove
favour
toxic
profil
therapeut
develop
briefli
mention
noncoval
strategi
base
short
peptid
abl
form
complex
cargo
without
requir
crosslink
chemic
modif
cpp
use
noncoval
approach
amphipath
charact
enabl
combin
electrostat
hydrophob
interact
cargo
amphipath
may
aris
either
primari
structur
secondari
structur
primari
amphipath
peptid
defin
sequenti
assembl
hydrophob
residu
hydrophil
residu
wherea
secondari
amphipath
peptid
gener
conform
state
allow
distribut
hydrophob
hydrophil
residu
opposit
side
molecul
though
origin
base
amphipath
peptid
noncoval
approach
extend
peptid
peptid
analogu
abl
selfassembl
on
form
stabl
cpp
complex
sever
report
improv
deliveri
mammalian
cell
noncoval
approach
origin
develop
deliveri
larg
molecul
sever
peptid
abl
bind
condens
dna
gala
kala
use
improv
gene
deliveri
divita
heitz
group
design
mpg
peptid
deliveri
singl
doubl
strand
short
on
strategi
extend
protein
peptid
develop
sinc
mpg
numer
cpp
complex
develop
deliveri
differ
type
on
includ
ao
sso
sirna
main
advantag
noncoval
strategi
coval
conjug
lie
simplic
protect
cpp
complex
confer
digest
nucleas
compar
chemic
cppon
conjug
noncoval
complex
usual
involv
onestep
process
consist
simpl
mix
partner
cpp
fig
cpp
complex
requir
chemic
cleavag
prevent
steric
hindranc
peptid
favour
better
releas
insid
target
cell
facilit
modif
increas
specif
andor
target
regard
mechan
intern
consensu
point
view
cell
entri
noncoval
complex
see
section
howev
complex
reli
electrostat
hydrophob
interact
posit
charg
cpp
neg
charg
on
cellular
uptak
mechan
could
also
control
structur
polymorph
peptid
particl
stabil
natur
complexesmembran
interact
interestingli
cpp
noncoval
complex
shown
enter
cell
direct
transloc
process
noncoval
cpp
enabl
wide
rang
chemic
modif
combin
modular
natur
peptid
result
cpp
on
particl
also
allow
new
develop
first
develop
mpg
base
peptideon
interact
investig
cpp
affin
fluoresc
spectrometri
measur
dissoci
constant
kd
well
optim
molar
ratio
andor
charg
ratio
obtain
stabl
complex
molar
ratio
mr
peptid
per
chargedcorrect
np
ratio
posit
charg
amino
acid
n
phosphat
group
p
estim
similar
approach
use
noncoval
cpp
hypnappna
cadi
sirna
condens
fluoresc
assay
also
combin
circular
dichroism
cd
analys
monitor
conform
chang
might
occur
presenc
cpp
complex
format
although
fluoresc
cd
investig
suggest
interact
format
cpp
complex
use
gel
shift
assay
gener
demonstr
format
complex
howev
none
give
clear
character
cpp
particl
term
colloid
properti
size
charg
shape
studi
colloid
properti
cpp
complex
therefor
wit
recent
year
method
use
nanomedicin
appli
order
character
size
surfac
charg
morpholog
cpp
complex
law
et
al
first
report
hydrodynam
diamet
zeta
potenti
r
sirna
noncoval
complex
uvvis
absorb
cd
investig
suggest
r
sirna
interact
size
zeta
potenti
measur
sever
charg
ratio
reveal
r
form
particl
sirna
hydrodynam
diamet
sirna
satur
zeta
potenti
increas
hydrodynam
diamet
particl
support
posit
contribut
guanidinium
group
r
surfac
charg
size
zeta
potenti
estim
parallel
sinc
accord
dvlo
theori
colloid
system
low
zeta
potenti
suggest
low
electrostat
repuls
induc
aggreg
particl
wherea
high
absolut
valu
zeta
potenti
indic
stabl
particl
suspens
light
investig
size
charg
gener
cpp
complex
differ
type
on
sirna
sso
ason
howev
paramet
might
differ
accord
cpp
natur
formul
protocol
exampl
kim
et
al
identifi
small
r
sirna
nanoparticl
nm
diamet
mv
zeta
potenti
chargecorrect
np
ratio
pb
whilst
cadi
sirna
nanoparticl
size
nm
surfac
charg
mv
whatev
mr
mm
nacl
cadi
sirna
nanoparticl
polydispers
index
pdi
suggest
homogen
unimod
nanoparticl
cpp
complex
size
biolog
activ
clearli
vari
mr
size
charg
also
depend
environ
import
sinc
nanoparticl
stabil
homogen
might
vari
accord
natur
buffer
describ
sirna
particl
addit
physiolog
condit
serum
addit
influenc
colloid
properti
sirna
complex
form
homogen
unimod
nanoparticl
nm
remain
stabl
water
whilst
presenc
serum
protein
induc
larger
particl
nm
wider
distribut
cpp
complex
also
stabil
specif
excipi
lactos
mannitol
albumin
sinc
shape
nanoparticl
also
influenc
bloodstream
circul
halflif
morpholog
pbn
studi
electron
microscopi
atom
forc
microscopi
afm
studi
point
globular
spheric
nanoobject
fine
colloid
character
suggest
redefinit
cpp
complex
regard
chemic
modif
includ
design
noncoval
cpp
well
discrep
formul
complex
appropri
term
peptidebasednanoparticl
pbn
propos
light
formul
pbn
clearli
becam
key
point
consid
develop
especi
regard
vivo
administr
pbn
aim
vivo
perspect
improv
membran
permeat
cell
target
abil
whilst
biocompat
biodegrad
minim
cytotox
inflammatori
respons
see
section
pbn
success
use
vivo
deliveri
antisens
on
sso
sirna
regard
sirna
first
report
pbnmediat
deliveri
sirna
vivo
involv
nl
peptid
cholesterol
oligodarginin
cholr
nl
use
vivo
deliveri
sirna
target
mous
blastocyt
one
earliest
transcript
factor
express
embryo
pluripot
fate
es
cell
depend
upon
tight
control
express
nl
base
nanoparticl
induc
sirnamedi
inhibit
regul
es
cell
prevent
specif
toward
mesoderm
differenti
cardiomyocyt
similarli
inject
pbn
inner
cell
mass
blastocyst
impair
cardiogenesi
earli
embryo
cholr
appli
deliveri
sirna
target
vegf
sivgef
cell
xenograft
tumour
intratumour
administr
cholr
sivgef
complex
induc
signific
inhibit
tumour
growth
associ
pronounc
decreas
vegf
level
tumour
suggest
synergist
effect
damino
acid
cpp
cholesterol
moieti
similar
approach
nl
modifi
shorten
cholesterolfunction
peptid
analogu
deliveri
sirna
target
cyclin
induc
signific
regul
protein
mrna
level
system
administr
nanoparticl
target
cyclin
prevent
tumour
growth
xenograft
tumour
mous
model
intraven
inject
mgkg
reduc
tumour
growth
day
administr
mgkg
pbn
entir
abolish
tumour
growth
addit
formul
mix
pbn
reveal
cholesterol
increas
biodistribut
sirna
tumour
maintain
sirna
plasma
cytokin
level
plasma
quantifi
order
assess
abil
sirna
sirna
formul
induc
innat
immun
respons
vivo
increas
cytokin
level
observ
h
inject
formul
suggest
lack
immun
respons
induct
similar
approach
test
vivo
rnai
silenc
hypoxanthin
phosphoribosyltransferas
gene
target
due
long
cellular
halflif
protein
h
minim
impact
viabil
transfect
cell
system
administr
sirna
nanoparticl
mgkg
induc
signific
regul
n
mrna
level
liver
kidney
lung
without
induct
immun
respons
addit
nanoparticl
also
use
rnaimedi
silenc
luciferas
lucsirna
mice
express
luciferas
liver
intraven
inject
lucsirna
mgkg
display
decreas
bioluminesc
week
reach
gene
silenc
whilst
nake
lucsirna
unabl
induc
rnai
respons
likewis
cholr
r
sirna
nanoparticl
formul
sirnamedi
knockdown
human
epiderm
growth
factor
receptor
human
ovari
adenocarcinoma
cell
reduct
express
associ
inhibit
xenograft
tumour
growth
intratumour
inject
r
sirna
nanoparticl
everi
day
dose
sirna
per
mous
significantli
reduc
tumour
growth
without
signific
toxic
furthermor
differ
strategi
investig
stabil
nanoparticl
increas
blood
circul
exemplifi
albuminor
polyethylen
glycol
peg
coat
nanoparticl
exampl
hou
cowork
shown
albuminco
formul
exhibit
remark
transfect
effici
attribut
ph
trigger
nanoparticl
disassembl
furthermor
tanaka
cowork
demonstr
intraven
inject
complex
significantli
higher
antitumour
effect
sarcomabear
mice
noncoval
cpp
test
vivo
formul
sirna
deliveri
howev
noncoval
strategi
also
intend
deliv
type
on
ason
sso
vivo
light
formul
antisens
cyclin
hypnappna
result
pbn
evalu
xenograft
mice
pbn
administr
intratumour
intraven
inject
everi
day
biolog
effect
antisens
hypnappna
evalu
monitor
tumour
growth
week
inject
intratumour
administr
pbn
induc
inhibit
tumour
growth
mg
dose
mg
dose
wherea
intraven
inject
reduc
tumour
growth
mg
dose
consequ
order
improv
vivo
stabil
pbn
small
amount
includ
formul
intraven
administr
mg
pbn
contain
significantli
improv
pbn
stabil
inhibit
tumour
growth
effici
data
emphas
potenti
noncoval
cpp
vivo
ason
deliveri
import
pegyl
nanoparticl
stabil
addit
physicochem
properti
pbn
specif
characterist
formul
address
paramet
affin
molar
charg
ratio
excipi
size
colloid
properti
strong
influenc
biolog
interact
minor
chang
major
impact
drug
deliveri
efficaci
thu
fda
draft
guidanc
liposom
product
physicochem
properti
specif
includ
morpholog
net
charg
particl
size
pbn
spectroscop
data
light
scatter
index
vitro
releas
content
peptideengag
pbn
versu
free
peptid
biodegrad
pbn
one
challeng
question
concern
cpp
mechan
peptid
enter
cell
earli
studi
use
fluoresc
dye
link
cpp
conclud
intern
energyand
temperatureindepend
howev
later
found
experiment
artefact
due
strong
cpp
adher
cell
membran
lead
fluoresc
overestim
andor
fixat
protocol
use
methanol
allow
cppdye
complex
enter
cell
recent
studi
suggest
cpp
uptak
take
place
endocytosi
energyindepend
transloc
balanc
two
pathway
influenc
factor
cpp
sequenc
temperatur
cpp
concentr
admit
biophys
method
cell
biolog
assay
biolog
endpoint
assess
activ
need
use
dissect
cell
import
mechan
molecul
approach
cell
first
encount
layer
oligosaccharidesth
endotheli
glycocalyx
network
membranebound
proteoglycan
glycoprotein
cover
endothelium
lumin
proteoglycan
particular
carri
larg
olink
oligosaccharid
consist
highli
neg
charg
repeat
disaccharid
unit
glycosaminoglycan
gag
heparan
sulphat
hs
gag
involv
cellular
bind
uptak
sever
virus
well
cation
cpp
polycation
nanoparticl
oligoarginin
bind
hs
affin
upper
nanomolar
rang
suggest
gag
may
act
cpp
receptor
review
interact
cation
cpp
gag
number
posit
charg
number
arginin
shown
critic
exampl
penetratinpna
conjug
mainli
intern
via
macropinocytosi
initi
hs
interact
cell
surfac
besid
import
role
posit
charg
sagan
cowork
also
show
strong
posit
correl
number
tryptophan
residu
gag
bind
cell
uptak
likewis
cadi
sirna
complex
interact
hspg
probabl
allow
bind
accumul
particl
cell
surfac
demonstr
electromobl
gel
shift
assay
nanoparticl
dissoci
sever
model
explain
direct
membran
transloc
cpp
propos
format
invert
micel
pore
format
toroid
barrel
slave
carpet
model
sinkingraft
model
model
initi
propos
uptak
membraneact
peptid
review
adapt
cpp
oligoarginin
transportan
likewis
amphipath
mpg
cadi
peptid
intern
via
direct
membran
transloc
basi
physicochem
investig
eg
circular
dichroism
fourier
transform
infrar
electrophysiolog
measur
model
membran
two
similar
model
propos
mpg
sirna
cadi
sirna
pbn
base
format
transient
porelik
structur
partial
conform
chang
take
place
upon
mpg
complex
nucleic
acid
increas
content
upon
associ
cell
membran
cadi
sirna
pbn
character
detail
review
cadymedi
cellular
uptak
sirna
extrem
rapid
moreov
intern
biolog
activ
cadi
sirna
occur
even
inhibit
mitochondri
oxid
phosphoryl
reveal
energyindepend
mechan
fluoresc
microscopi
reveal
neither
transferrin
coloc
cadi
sirna
nanoparticl
wherea
coloc
lysotrack
observ
extent
data
support
uptak
mechan
larg
independ
classic
endocytosi
degrad
nanoparticl
via
lysosom
pathway
apart
case
describ
section
present
consensu
cell
uptak
occur
mainli
endocytosi
argininerich
cpp
least
low
concentr
whether
clathrinco
pit
endocytosi
macropinocytosi
anoth
endocyt
rout
use
still
matter
debat
rout
might
differ
cell
type
natur
payload
concentr
intern
mechan
mainli
character
use
hela
splice
redirect
assay
fig
correl
cellular
uptak
biolog
effici
cpppna
cpppmo
conjug
sever
conjug
analys
detail
ly
pnali
rxr
cell
uptak
energydepend
lead
sequestr
conjug
cytoplasm
vesicl
endocyt
mechan
intern
limit
provid
endosom
sequestr
payload
well
illustr
two
follow
set
data
stearyl
version
transportan
abl
complex
sso
sso
pbn
rather
effici
hela
splicingredirect
assay
howev
signific
part
complex
still
remain
entrap
endosom
releas
upon
chloroquin
treatment
base
result
endosomolyt
trifluoromethylquinolin
qn
moieti
graft
cpp
lead
larg
improv
cytoplasm
deliveri
transfect
increas
splice
redirect
activ
likewis
effici
transfect
sirna
promot
gene
silenc
low
concentr
varianc
formul
along
line
recent
could
relat
high
effici
mdx
skelet
muscl
effici
releas
endocyt
vesicl
intern
via
caveolaedepend
endocytosi
varianc
conjug
intern
clathrindepend
endocytosi
primari
mdx
cardiomyocyt
less
effici
releas
endocyt
vesicl
lower
exon
skip
activ
sever
strategi
use
studi
cellular
intern
cppon
conjug
cpp
complex
biophys
character
cppon
use
circular
dichroism
infrar
spectroscopi
dynam
light
scatter
insert
studi
phospholipid
layer
inhibit
specif
endocyt
pathway
assess
effect
cppon
intern
biolog
activ
coloc
microscopi
studi
associ
cppon
fluoresc
label
endocyt
marker
associ
cpp
membran
induc
modif
sever
physic
properti
surfac
pressur
monolay
langmuir
blodgett
secondari
structur
peptid
ftir
cd
etc
deform
lipid
bilay
due
hydrophob
hydrophil
interact
compon
well
peptid
local
membran
also
assess
use
nmr
xray
diffract
coupl
plasmon
waveguid
reson
epr
fret
assess
endosom
escap
directli
turn
difficult
monitor
use
artifici
model
liposom
leakag
assay
differ
protocol
develop
use
larg
unilamellar
vesicl
luv
entrap
dye
calcein
carboxyfluorescein
ant
fluoresc
dye
dpx
quencher
cellulo
clathrinmedi
endocytosi
predominantli
character
use
transferrin
uptak
cell
inde
inhibit
clathrinspecif
sirna
via
cell
transfect
cell
mutant
form
dynamin
howev
dynamin
known
regul
endocyt
membran
traffick
pathway
altern
pharmacolog
inhibitor
chlorpromazin
dynasor
dynamin
inhibitor
use
inhibit
pathway
even
reagent
caus
signific
cell
toxic
use
short
incub
time
potassium
deplet
hyperton
medium
incub
also
commonli
use
investig
clathrinmedi
endocytosi
caveola
invagin
plasma
membran
local
lipid
raft
number
ligand
cholera
toxin
b
viru
albumin
shown
intern
less
specif
via
caveola
glycosphingolipid
analogu
lactosylceramid
laccer
fluoresc
probe
also
shown
intern
via
rout
may
repres
select
marker
pathway
rang
pharmacolog
inhibitor
pathway
describ
main
agent
deplet
cholesterol
synthesi
lovastatin
agent
rapidli
extract
cholesterol
lipid
raft
cholesterolinteract
molecul
antibiot
nystatin
filipin
dowdi
futaki
colleagu
shown
tat
argininerich
cpp
induc
ubiquit
form
fluidphas
endocytosi
term
micropinocytosi
exampl
uptak
octaarginin
peptid
hela
cell
significantli
suppress
macropinocytosi
inhibitor
ethylisopropylamilorid
eipa
factin
polymer
inhibitor
cytochalasin
suggest
role
macropinocytosi
uptak
peptid
mention
cpp
taken
primarili
endocyt
pathway
order
promot
endosom
escap
increas
transfect
effici
cpp
mani
differ
strategi
use
mention
insert
endosomolyt
moieti
section
addit
strategi
describ
sinc
endosom
low
ph
research
incorpor
histidin
residu
append
oligohistidin
tail
cpp
sequenc
aim
capit
proton
spong
effect
see
review
due
proton
ph
imidazol
ring
histidin
weak
base
counterbal
accumul
proton
gener
specif
atpas
insid
acid
vesicl
neutral
lumen
endocyt
vesicl
increas
osmolar
consequ
endosom
vesicl
swell
content
deliv
cytosol
exploit
success
tatcpp
microspher
coat
ornithin
histidin
repeat
h
selfassembl
nanoconstruct
amphiphil
copolym
see
review
mason
cowork
focus
amphipath
peptid
incorpor
ph
sensit
residu
histidin
residu
peptid
uncharg
neutral
ph
ph
endosom
lumen
drop
side
chain
becom
proton
larg
number
peptid
releas
complex
adopt
conform
align
membran
induc
membran
disord
group
focus
addit
cholesterol
fatti
acid
modif
exampl
cholr
improv
sirna
deliveri
mous
model
bear
subcutan
tumour
tatpnamedi
splice
correct
increas
two
order
magnitud
conjug
decano
acid
stearyl
cpp
repres
anoth
strategi
increas
endosom
escap
consequ
increas
transfect
effici
sirna
phosphorothio
rna
alreadi
detail
section
vivo
applic
frequent
modif
involv
graft
polyethylen
glycol
peg
moieti
prevent
rapid
clearanc
report
deliveri
antisensecyclin
block
tumour
growth
vivo
upon
intratumour
intraven
inject
pegyl
significantli
improv
complex
stabil
effici
context
clinic
translat
crucial
improv
tissu
specif
cpp
function
screen
vivo
phage
display
enabl
identif
numer
peptid
home
specif
variou
organ
normal
patholog
condit
exampl
five
residu
home
peptid
creka
identifi
vivo
screen
phagedisplay
peptid
librari
tumourbear
mmtvpymt
transgen
breast
cancer
mice
combin
pvec
peptid
yield
cpp
tumour
home
specif
despit
huge
potenti
clinic
use
nucleic
acidsbas
drug
limit
poor
biodistribut
cell
penetr
peptid
therefor
consid
possibl
strategi
improv
passag
across
biolog
barrier
intracellular
deliveri
review
extens
chapter
coval
conjug
neutral
antisens
mimic
noncoval
complex
either
charg
antisens
on
sirna
engin
sever
construct
undergon
extens
evalu
anim
model
mainli
mice
acquir
eg
viral
infect
cancer
particular
genet
eg
duchenn
muscular
dystrophi
human
diseas
cppdeliveri
convincingli
shown
increas
significantli
effici
nucleic
acid
cargo
clinic
trial
howev
yet
start
knowledg
extens
studi
biodistribut
possibl
toxic
effect
particular
complet
despit
mani
studi
mechan
respons
extravas
cellular
traffick
cppdrug
conjug
complex
still
poorli
understood
direct
transloc
across
cell
membran
appear
oper
instanc
case
howev
cell
intern
occur
endocytosi
escap
endocyt
vesicl
limit
biolog
effici
likewis
cpp
deliveri
occur
similar
effici
tissu
system
administr
understand
better
limit
obvious
help
engin
new
cpp
gener
superior
potenti
target
variou
tissu
patholog
condit
deliv
payload
within
appropri
cellular
compart
effort
direct
alreadi
start
describ
chapter
much
remain
done
